Clinical Trial Update: Safety and Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in 2 to 70 Years Old Healthy People in China [Phase 3]

View source ↗

Summary

Phase 3 trial in healthy participants aged 2-70 in China evaluates safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine (PPSV23); the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Conditions: Healthy | Phase 3 | Status: COMPLETED